HRT Financial’s Lipocine LPCN Stock Holding History

HRT Financial’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,422	Closed	-$23K	–	3519
2021 Q4	$23K	Buy	+1,422	New	+$26.4K	﹤0.01%	2934
2021 Q2	–	Sell	-853	Closed	-$21K	–	3226
2021 Q1	$21K	Buy	+853	New	+$24.6K	﹤0.01%	2595

Other funds holding LPCN

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

HRT Financial's LPCN Position: Q1 2022 in Review

HRT Financial sold out of Lipocine (LPCN) in Q1 2022, closing a stake of 1,422 shares — an estimated $23K sold.

HRT Financial first reported a position in LPCN in Q1 2021 and held it in 2 quarters. The position peaked at $23K in Q4 2021. 44 funds tracked by Wall St. Rank hold LPCN as of Q1 2022.

HRT Financial reported no remaining Lipocine position as of Q1 2022 after selling out during the quarter.
HRT Financial sold 1,422 Lipocine shares in Q1 2022, an estimated $23K.
HRT Financial first reported a position in Lipocine in Q1 2021 and held it in 2 quarters.
HRT Financial's Lipocine position peaked at $23K in Q4 2021.
44 funds tracked by Wall St. Rank held Lipocine as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.